| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/28/2004 | US20040213761 administering to a patient an effective amount of an agonist or antagonist of IL-23, for wound healing |
| 10/28/2004 | US20040213756 Methods and compositions to treat myocardial conditions |
| 10/28/2004 | US20040213753 administrating to a skin or hair of a candidate a sponge protein hydrolysate which is a product by acidic hydrolysis of sponge skeleton fibers (spongin fibers) obtained from refined sponges as the raw material in an amount effective to stimulate cell growth of the skin or hair |
| 10/28/2004 | US20040213745 Suitable for reconstitution and parenteral administration |
| 10/28/2004 | DE10297369T5 Anwendung von Oligosacchariden in kosmetischen oder dermatologischen Zusammensetzungen zum Stimulieren der Haftung von Keratinozyten an den Hauptproteinen der Lederhaut-Epidermis-Verbindung und zum Wiederherstellen der Epidermiskohäsion Application of oligosaccharides in cosmetic or dermatological compositions for stimulating the adhesion of keratinocytes to the main proteins of the dermis-epidermis compound and for restoring the Epidermiskohäsion |
| 10/28/2004 | CA2523864A1 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 10/28/2004 | CA2522802A1 Biologically active substance-immobilized device |
| 10/28/2004 | CA2522544A1 Process for isolating and purifing ovine hyaluronidase |
| 10/28/2004 | CA2522322A1 Agent for treating diabetes mellitus |
| 10/28/2004 | CA2522203A1 Identification of n-alkylglycine trimers for induction of apoptosis |
| 10/28/2004 | CA2522106A1 Cellular preparation |
| 10/28/2004 | CA2522104A1 Vav inhibition in graft rejection |
| 10/28/2004 | CA2522098A1 Absorption enhancers such as bht, bha or propylgallate |
| 10/28/2004 | CA2522082A1 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| 10/28/2004 | CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling |
| 10/28/2004 | CA2521987A1 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 10/28/2004 | CA2521979A1 Compositions and methods related to production of erythropoietin |
| 10/28/2004 | CA2521965A1 Somatostatin-dopamine chimeric analogs |
| 10/28/2004 | CA2521839A1 Augmented cognitive training |
| 10/28/2004 | CA2521809A1 Improved heat shock protein-based vaccines and immunotherapies |
| 10/28/2004 | CA2521808A1 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 10/28/2004 | CA2521718A1 Biodegradable glucosaminemuramyl peptides for apoptosis modulation |
| 10/28/2004 | CA2521678A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 10/28/2004 | CA2521650A1 Interferon beta in severe acute respiratory syndrome (sars) |
| 10/28/2004 | CA2521381A1 Method for preparation of site-specific protein conjugates |
| 10/28/2004 | CA2521109A1 Anti-tumor vasculature effects of human serum albumin derivatives |
| 10/28/2004 | CA2520970A1 Hemophilia treatment by inhalation of coagulation factors |
| 10/28/2004 | CA2520518A1 Method for treatment of angiogenic disorders |
| 10/28/2004 | CA2520029A1 Slurp-1 compositions and methods of use thereof |
| 10/28/2004 | CA2518529A1 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 10/28/2004 | CA2518079A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| 10/28/2004 | CA2517154A1 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 10/28/2004 | CA2463487A1 Tumours treating combinations, compositions and methods |
| 10/28/2004 | CA2463464A1 Methods of treatment and compositions therefor |
| 10/27/2004 | EP1471144A1 Biological variability of asthma associated factor, AAF2 (IL-9 receptor), useful in treating and diagnosing atopic allergies including asthma and related disorders |
| 10/27/2004 | EP1471143A1 Rheumatoid arthritis disease sensitive gene, its protein, method and kit of judging the onset of rheumatoid arthritis using the same, and method and drugs for treating rheumatoid arthritis |
| 10/27/2004 | EP1471075A2 Human nucleic acid sequences expressed in pancreatic carcinomas |
| 10/27/2004 | EP1471074A2 Methods for improving the conformation of proteins by means of reducing agents |
| 10/27/2004 | EP1471073A2 Hepatitis C virus asialoglycoproteins |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1471034A2 Therapeutic calcium phosphate particles and methods of manufacture and use |
| 10/27/2004 | EP1470826A1 Decoy-containing pharmaceutical compositions and method of using the same |
| 10/27/2004 | EP1470821A2 Cell therapy method for the treatment of tumours |
| 10/27/2004 | EP1470423A2 Unc-13 in the modulation of neurotransmission and secretion events |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470249A2 Effectors of innate immunity |
| 10/27/2004 | EP1470246A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 10/27/2004 | EP1470240A2 Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2 |
| 10/27/2004 | EP1470226A1 Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
| 10/27/2004 | EP1470224A1 Molecular libraries |
| 10/27/2004 | EP1470223A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 10/27/2004 | EP1470218A2 Corona-virus-like particles comprising functionally deleted genomes |
| 10/27/2004 | EP1470216A2 Hair follicle growth |
| 10/27/2004 | EP1470157A2 Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof |
| 10/27/2004 | EP1470155A2 Pluripotency determining factors and uses thereof |
| 10/27/2004 | EP1470154A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 10/27/2004 | EP1470153A2 Two gonadotropin releasing hormones and a method to isolate the same |
| 10/27/2004 | EP1470147A2 Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats |
| 10/27/2004 | EP1470145A2 Methods and materials for modulating p2x2 |
| 10/27/2004 | EP1470144A2 Oligonucleotides comprising alternating segments and uses thereof |
| 10/27/2004 | EP1470141A2 Glycosulfopeptide inhibitors and methods of use thereof |
| 10/27/2004 | EP1470115A1 Treatment of male sexual dysfunction |
| 10/27/2004 | EP1469888A2 Stem cell screening and transplantation therapy for hiv infection |
| 10/27/2004 | EP1469887A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 10/27/2004 | EP1469883A2 Compositions and methods for regulating lymphocyte activation |
| 10/27/2004 | EP1469880A2 Method for reducing morbidity and mortality in critically ill patients |
| 10/27/2004 | EP1469878A2 Fgfr agonists |
| 10/27/2004 | EP1469877A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
| 10/27/2004 | EP1469876A2 Antimicrobial cationic peptides and formulations thereof |
| 10/27/2004 | EP1469875A1 Compositions and methods for modulating connexin hemichannels |
| 10/27/2004 | EP1469874A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 10/27/2004 | EP1469871A2 Method of treating apoptosis and compositions thereof |
| 10/27/2004 | EP1469869A2 Peptide useful in immunomodulation |
| 10/27/2004 | EP1469850A1 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469840A1 Cyclosporin-containing sustained release pharmaceutical composition |
| 10/27/2004 | EP1469834A1 Multi-stage oral drug controlled-release system |
| 10/27/2004 | EP1469827A2 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 10/27/2004 | EP1469812A2 Oral insulin therapy |
| 10/27/2004 | EP1469811A2 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
| 10/27/2004 | EP1469741A1 A process for the extraction,purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent |
| 10/27/2004 | EP1469734A1 Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| 10/27/2004 | EP1469730A2 Methods and compositions for treating parkinson's disease |
| 10/27/2004 | EP1418933A4 Process for preparing glycopeptide phosphonate derivatives |
| 10/27/2004 | EP1299126B1 Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases |
| 10/27/2004 | EP1212269B1 Methods for preparing n- (aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds |
| 10/27/2004 | EP1204407B1 Implantable active ingredient depot |
| 10/27/2004 | EP1169057B1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 10/27/2004 | EP1165117B1 Use of interferon-beta in the manufacture of a medicament for the treatment of ewing's sarcoma and eoe |
| 10/27/2004 | EP1141022B1 Serine protease inhibitor |
| 10/27/2004 | EP1117690A4 Polymeric hemoglobin mutants |
| 10/27/2004 | EP1107793B1 Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| 10/27/2004 | EP1107777B1 Stabilized pharmaceutical composition in lyophilized form |
| 10/27/2004 | EP1097209B1 Inhibition of alopecia |
| 10/27/2004 | EP1064395A4 Novel molecules of the g protein-coupled heptahelical receptor superfamily and uses therefor |
| 10/27/2004 | EP1027027A4 Therapeutic method |
| 10/27/2004 | EP1012603B1 Functional fragments of hiv-1 vpr protein and methods of using the same |
| 10/27/2004 | EP1000153B1 Crustacean antimicrobial peptides |
| 10/27/2004 | EP0998577B1 Conjugates of transporter peptides and nucleic acid analogs, and their use |